- Home
- SBH vs CGEM Comparison
SBH vs CGEM Comparison
Compare SBH & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBH | CGEM |
|---|---|---|
| Founded | 1964 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SBH | CGEM |
|---|---|---|
| Price | $14.70 | $17.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $17.25 | ★ $30.13 |
| AVG Volume (30 Days) | ★ 1.3M | 741.8K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.17 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $3,701,424,000.00 | N/A |
| Revenue This Year | $2.20 | N/A |
| Revenue Next Year | $1.82 | $5.20 |
| P/E Ratio | $16.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.37 | $5.68 |
| 52 Week High | $17.92 | $19.43 |
Technical Indicators
Market Signals| Indicator | SBH | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 51.13 |
| Support Level | $13.80 | $17.19 |
| Resistance Level | $15.65 | $19.10 |
| Average True Range (ATR) | 0.58 | 0.89 |
| MACD | -0.06 | -0.18 |
| Stochastic Oscillator | 40.07 | 45.41 |
Price Performance
Historical ComparisonAbout SBH Sally Beauty Holdings Inc. (Name to be changed from Sally Holdings Inc.)
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. The company operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, Netherlands, and other geographical regions. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. The products offered by the company include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.